NeurAxis, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $76.7M
- Price
- $6.15
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.91%
- Volume
- 96.7K
About
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
Quick stats
Shares outstanding12.5M
Computed float8.7M
Float / shares70.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001933567
Websitehttps://neuraxis.com
AI Summary
AI-generated1/10
majorbullishearnings
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth
NeurAxis reported Q2 2026 revenue of $1.9 million, up 116% year-over-year, driven by the adoption of the Category I CPT code for its PENFS technology and increased payer coverage.
Gross margin expanded by 230 basis points to 85.9% as revenue shifted toward fully reimbursed procedures, while the company held $8.3 million in cash following a $2.5 million capital raise.
Operationally, NeurAxis secured the first-ever FDA clearance for functional dyspepsia treatment and a Veterans Affairs Federal Supply Schedule contract, significantly broadening its commercial pathway.
Red flags
- General and administrative expenses increased 46% year-over-year to $2.6 million, contributing to a wider net loss.